178 related articles for article (PubMed ID: 32846366)
1. The selective 5-HT
Depoortere R; Johnston TH; Fox SH; Brotchie JM; Newman-Tancredi A
Parkinsonism Relat Disord; 2020 Sep; 78():151-157. PubMed ID: 32846366
[TBL] [Abstract][Full Text] [Related]
2. The selective 5-HT
Fisher R; Hikima A; Morris R; Jackson MJ; Rose S; Varney MA; Depoortere R; Newman-Tancredi A
Neuropharmacology; 2020 May; 167():107997. PubMed ID: 32057799
[TBL] [Abstract][Full Text] [Related]
3. The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
McCreary AC; Varney MA; Newman-Tancredi A
Neuropharmacology; 2016 Jun; 105():651-660. PubMed ID: 26777281
[TBL] [Abstract][Full Text] [Related]
4. NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
Iderberg H; McCreary AC; Varney MA; Kleven MS; Koek W; Bardin L; Depoortère R; Cenci MA; Newman-Tancredi A
Exp Neurol; 2015 Sep; 271():335-50. PubMed ID: 26037043
[TBL] [Abstract][Full Text] [Related]
5. The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque.
Huot P; Johnston TH; Fox SH; Newman-Tancredi A; Brotchie JM
Neuropharmacology; 2015 Oct; 97():306-11. PubMed ID: 26071982
[TBL] [Abstract][Full Text] [Related]
6. Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia.
Bézard E; Muñoz A; Tronci E; Pioli EY; Li Q; Porras G; Björklund A; Carta M
Neurosci Res; 2013 Dec; 77(4):242-6. PubMed ID: 24135129
[TBL] [Abstract][Full Text] [Related]
7. NLX-112, a highly selective 5-HT
Depoortère R; Bergman J; Beardsley PM; Desai RI; Paronis CA; Walentiny DM; Varney MA; Newman-Tancredi A
Neuropharmacology; 2022 Jun; 210():109025. PubMed ID: 35276118
[TBL] [Abstract][Full Text] [Related]
8. Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.
Johnston TH; Geva M; Steiner L; Orbach A; Papapetropoulos S; Savola JM; Reynolds IJ; Ravenscroft P; Hill M; Fox SH; Brotchie JM; Laufer R; Hayden MR
Mov Disord; 2019 May; 34(5):708-716. PubMed ID: 30575996
[TBL] [Abstract][Full Text] [Related]
9. TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque.
Johnston TH; Huot P; Fox SH; Koprich JB; Szeliga KT; James JW; Graef JD; Letchworth SR; Jordan KG; Hill MP; Brotchie JM
Neuropharmacology; 2013 Oct; 73():337-47. PubMed ID: 23770260
[TBL] [Abstract][Full Text] [Related]
10. Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque.
Huot P; Johnston TH; Koprich JB; Winkelmolen L; Fox SH; Brotchie JM
Neurobiol Aging; 2012 Jan; 33(1):207.e9-19. PubMed ID: 21051107
[TBL] [Abstract][Full Text] [Related]
11. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
12. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
[TBL] [Abstract][Full Text] [Related]
13. Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors.
Paquette MA; Martinez AA; Macheda T; Meshul CK; Johnson SW; Berger SP; Giuffrida A
Eur J Neurosci; 2012 Nov; 36(9):3224-34. PubMed ID: 22861201
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect of serotonin 1A and serotonin 1B/D receptor agonists in the treatment of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
Thomsen M; Stoica A; Christensen KV; Fryland T; Mikkelsen JD; Hansen JB
Exp Neurol; 2022 Dec; 358():114209. PubMed ID: 35988699
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
[TBL] [Abstract][Full Text] [Related]
16. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
Bezard E; Tronci E; Pioli EY; Li Q; Porras G; Björklund A; Carta M
Mov Disord; 2013 Jul; 28(8):1088-96. PubMed ID: 23389842
[TBL] [Abstract][Full Text] [Related]
17. DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
Johnston TH; Versi E; Howson PA; Ravenscroft P; Fox SH; Hill MP; Reidenberg BE; Corey R; Brotchie JM
Neuropharmacology; 2018 Mar; 131():116-127. PubMed ID: 29197517
[TBL] [Abstract][Full Text] [Related]
18. Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys.
Grégoire L; Jourdain VA; Townsend M; Roach A; Di Paolo T
Parkinsonism Relat Disord; 2013 May; 19(5):508-14. PubMed ID: 23402994
[TBL] [Abstract][Full Text] [Related]
19. Characterizing the differential roles of striatal 5-HT
Meadows SM; Chambers NE; Conti MM; Bossert SC; Tasber C; Sheena E; Varney M; Newman-Tancredi A; Bishop C
Exp Neurol; 2017 Jun; 292():168-178. PubMed ID: 28342749
[TBL] [Abstract][Full Text] [Related]
20. Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Fidalgo C; Ko WK; Tronci E; Li Q; Stancampiano R; Chuan Q; Bezard E; Carta M
Neuroscience; 2015 Jul; 298():389-96. PubMed ID: 25907446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
